Company Overview and News

 
Spotlight on CIMB

2018-09-28 thestar.com.my
The face of CIMB: Nazir has spent close to three decades at the banking group, with 15 of those years as CEO.
1155 1023 5665 MLYBY SMEBF MLYNF Y03 4197 5274 5355 CIMDF 5133

 
Stock With Momentum: Daiman Development

2018-08-30 theedgemarkets
TRADING in the shares of Daiman Development (fundamental: 2.25/3, valuation: 2/3) triggered our momentum algorithm yesterday for the first time this year.
5355

 
FBM KLCI closes higher on optimism over US-Mexico trade deal

2018-08-28 theedgemarkets
KUALA LUMPUR (Aug 28): The FBM KLCI continued with its strong momentum with sentiment further lifted by external optimism on news of the United States-Mexico trade deal.
5355

 
FBM KLCI up 9.31pts on US-Mexico trade agreement

2018-08-28 theedgemarkets
KUALA LUMPUR (Aug 28): The FBM KLCI rose 9.31 points or 0.51% as the US-Mexico trade agreement eased global concerns over the US's stance on world trade.
BATS 4162 5355

 
Daiman hits limit up after receiving privatisation offer

2018-08-28 theedgemarkets
KUALA LUMPUR (Aug 28): Daiman Development Bhd shares rose as much as 65 sen or 30% to RM2.82 so far today after the property developer said yesterday major shareholders requested Daiman Development to undertake a selective capital reduction and repayment (SCR) at RM3 a share.
BSMAF 5355 1818

 
Daiman jumps 30% in early trade on privatisation plan

2018-08-28 thestar.com.my
KUALA LUMPUR: Shares in Daiman Development Bhd jumped as much as 29.95%, almost hitting the limit-up threshold in early trade Tuesday after the company announced its privatisation plan.
BSMAF 5355 1818

 
Trading ideas: Vertice, Daiman, Padini, Matrix Concept, IOI Properties

2018-08-28 thestar.com.my
KUALA LUMPUR: Vertice Bhd, Daiman Development Bhd , Padini Holdings Bhd , Matrix Concepts Holdings Bhd and IOI Properties Group Bhd are among the stocks to watch, according to JF Apex Research.
5249 9385 7052 5236 5355

 
Major shareholders propose privatisation of Daiman

2018-08-28 theedgemarkets
KUALA LUMPUR: The major shareholders of Daiman Development Bhd have proposed to undertake a selective capital reduction (SCR) and repayment exercise to take the company private at RM3 a share or RM295.48 million in total.
BSMAF 5355 1818

 
Daiman major shareholders plan to take company private

2018-08-27 thestar.com.my
The integrated township of Taman Daiman Jaya offers an affordable range of houses situated within close proximity to a wealth of amenities – just beyond the doorstep of its residents. Filepic dated Jan 24 2018.
5355

 
Daiman Development, Gamuda, Taliworks, Top Glove, Matrix Concept, Vertice, BIMB, IOI Properties, Utusan, WCT and Watta

2018-08-27 theedgemarkets
KUALA LUMPUR (Aug 27): Based on corporate announcements and news flow today, stocks in focus on Tuesday (Aug 28) may include Daiman Development Bhd, Gamuda Bhd, Taliworks Corp Bhd, Top Glove Corp Bhd, Matrix Concepts Holdings Bhd, Vertice Bhd, BIMB Holdings Bhd, IOI Properties Group Bhd, Utusan Melayu (Malaysia) Bhd, WCT Holdings Bhd and Watta Holding Bhd.
7240 7113 TPGVF 9679 7226 5355 TGLVY 5249 5754 5258 5236 BSMAF 1818

 
Major shareholders propose privatisation of Daiman Development

2018-08-27 theedgemarkets
KUALA LUMPUR (Aug 27): The major shareholders of Daiman Development Bhd have proposed to undertake a selective capital reduction (SCR) and repayment exercise to take the company private at RM3 a share or RM295.48 million in total.
BSMAF 5355 1818

 
Daiman says share trade to be suspended from 9am today

2018-08-27 theedgemarkets
KUALA LUMPUR (Aug 27): Daiman Development Bhd's share trade will be suspended from 9am today pending a material announcement, the property developer said in a statement on Bursa Malaysia's website.
BSMAF 5355 1818

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...